GMAB News and Press, Genmab A/S From 10/12/19

Creating a list of companies that will make my elite list of 2029 investments that will have increased in value by a factor of 10 or more is a major challenge for more than one reason. As I stated in my previous article, in our fast moving world, industries unknown today may be household names...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Seven biotech companies with initial valuations north of $1 billion began trading during the first nine months of 2019. Overall, these companies performed well. Their average and median returns were 13% and 14% respectively. In comparison, the SPDR S&P 500 ETF (NYSEARCA: SPY) and the Fide...

AbbVie (NYSE: ABBV ) upgraded to Buy with a $79 (14% upside) price target at UBS. Shares up  2%  premarket. More news on: AbbVie Inc., Seattle Genetics, Inc., Varian Medical Systems, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Genmab GMAB has entered into a strategic collaboration agreement with Tempus, to research and develop novel targets. More news on: Genmab A/S, Genmab A/S, Read more ...

Sophisticated pharma investors will need to review the IGM Biosciences ( IGMS )' preclinical data. Janus Capital Management acquired shares, and the company holds a significant amount of cash. It means that preclinical research impressed institutional investors and may impress others. Having s...

Novartis (NYSE: NVS ) announces positive data from two Phase 3 clinical trials, ASCLEPIOS I and ASCLEPIOS II , evaluating monthly injections of ofatumumab versus daily oral doses of teriflunomide [Sanofi's (NASDAQ: SNY ) Aubagio] in adult patients with relapsing forms of multiple sclero...

Japan's Ministry of Health, Labor and Welfare approves Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech's Darzalex (daratumumab), combined with Takeda's Velcade (bortezomib), melphalan and prednisone, for newly diagnosed multiple myeloma (MM) patients who are ineligible for autologo...

Genmab A/S (NASDAQ: GMAB ) initiated with Overweight rating and $30 (58% upside) price target at Morgan Stanley. Initiated with Outperform rating and $23 price target at RBC. Shares up  1%  premarket. More news on: Genmab A/S, Fulcrum Therapeutics, Inc., Mirum Pharmaceuticals, In...

A Kansas bank and a Chinese fintech are scheduled for the week ahead, the last crop of offerings before the IPO market's annual August break. CrossFirst Bankshares (CFB) has about $4.6 billion in assets, with seven locations across KS, OK, TX, and MO. While its efficiency ratio and ROE are b...